论文部分内容阅读
目的:对直肠癌患者进行联合贝伐单抗新辅助化疗的临床病理进行评估,研究贝伐单抗对肿瘤组织微血管的影响。方法:回顾性分析在我院普外科治疗的47例直肠癌患者进行联合或不联合贝伐单抗(Bev)的新辅助化疗(NAC)治疗,用最大肿瘤直径评估肿瘤客观反应,用肿瘤消退分级评估肿瘤病理反应。结果:有31例(66%)患者进行联合贝伐单抗(Bev)的新辅助化疗治疗(联合Bev组)和其他16例患者进行不联合Bev的新辅助化疗治疗(不联合Bev组)。联合Bev组的肿瘤客观反应率明显高于不联合Bev组(64.5 vs.25.0%,P=0.015)。联合Bev组(41.9%)的病理反应率高于不联合Bev组(41.9%vs.12.5%,p=0.052),但并没有明显差异。联合Bev组的微血管密度(MVD)低于不联合Bev组。结论:联合Bev的新辅助化疗治疗患者的靶向和病理反应好于不联合Bev新辅助化疗的患者。联合Bev治疗患者的肿瘤组织的(MVD)受到抑制。
OBJECTIVE: To evaluate the clinicopathological features of neoadjuvant chemotherapy combined with bevacizumab in patients with rectal cancer and to study the effect of bevacizumab on the microvessel of tumor tissue. Methods: Forty-seven patients with rectal cancer undergoing general surgery in our hospital were retrospectively analyzed for neoadjuvant chemotherapy (NAC) with or without bevacizumab (Bev). The objective tumor response was assessed using the largest tumor diameter, Hierarchical evaluation of tumor pathological response. RESULTS: Twenty-one patients (66%) underwent neoadjuvant chemotherapy with bevacizumab (Bev group) and 16 patients underwent neoadjuvant chemotherapy without Bev (without Bev group). The objective tumor response rate in the Bev group was significantly higher than that in the non-Bev group (64.5 vs.25.0%, P = 0.015). The rate of pathological response in the Bev group (41.9%) was higher than that in the non-Bev group (41.9% vs. 12.5%, p = 0.052), but there was no significant difference. The microvessel density (MVD) in the Bev group was lower than that in the Bev group. Conclusions: The target and pathological response of neoadjuvant chemotherapy combined with Bev is better than that of patients without Bev neoadjuvant chemotherapy. Tumor tissue (MVD) in patients treated with Bev was inhibited.